Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | CCR2 | P41597 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140018 | 0.91 | KMT2A (0.52) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL16020329 | 0.86 | CCR2 (0.54) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL16017569 | 0.83 | CCR2 (0.52) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL13975944 | 0.83 | CCR2 (0.52) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL16020309 | 0.82 | ALDH1A1 (0.53) | KMT2AMEN1CCR2ALDH1A1KDM4E | |
| SCHEMBL16020358 | 0.80 | LMNA (0.54) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL24139765 | 0.79 | SLC40A1 (0.56) | KMT2AMEN1CYP2C9ALDH1A1METAP2 | |
| SCHEMBL24140017 | 0.77 | LMNA (0.51) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL16017575 | 0.77 | LMNA (0.51) | KMT2AMEN1CCR2CYP1A2CYP3A4 | |
| SCHEMBL24139998 | 0.77 | WDR5 (0.46) | KMT2AMEN1CCR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | KMT2A 1043/4885MEN1 2039/4885CCR2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.